PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination
December 06, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
OncoResponse Appoints Sean McCarthy to Board of Directors
July 07, 2021 07:00 ET
|
OncoResponse, Inc.
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to...
OncoResponse Appoints Chris Russell as Chief Financial Officer
May 11, 2021 07:00 ET
|
OncoResponse, Inc.
SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to...
VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
September 24, 2018 06:00 ET
|
VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...